Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02.
On May 31, 2017, the Company sold to unaffiliated investors 892,857 shares of its common stock at a price of $0.14 per share and issued to such investors 669,643 Class A warrants (exercisable at $0.175 per share for a period of 5 years) for an aggregate of $125,000.
On June 5, 2017, the Company sold to an unaffiliated investor 3.3 million shares of its common stock at a price of $0.14 per share and issued to such investor 2,475,000 Class A warrants (exercisable at $0.175 per share for a period of 5 years) for an aggregate of $462,000.
On June 29, 2017, the Company sold to an unaffiliated investor 555,556 shares of its common stock at a price of $0.18 per share and issued to such investor 416,667 Class A warrants (exercisable at $0.26 per share for a period of 5 years) and 416,667 Class B warrants (exercisable at $1.00 per share for a period of 3 months) for an aggregate of $462,000.
On July 6, 2017, the Company sold to investors 1,312,500 shares of its common stock at a price of $0.16 and 1,000,000 shares of its common stock at a price of $0.18.
On July 17, 2017, holders of 16,071,428 Class A warrants of the Company exercised such warrants on a cashless basis in exchange for the delivery of 6,939,934 shares of the Company’s common stock.
On July 17, 2017, the Company extended the expiration date of 1,038,460 Class B warrants of the Company, having an exercise price of $1.00, from July 17, 2017 to October 17, 2017.
The securities issued on July 17, 2017 were issued to the exemption from the registration requirements afforded by Section 3(a)(9) of the Securities Act, and the other securities issued above were issued to the exemption from the registration requirements afforded by Section 4(a)(2) and Regulation D of the Securities Act.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
